Clinical Trials
34
Active:22
Completed:12
Trial Phases
3 Phases
Phase 1:1
Phase 2:6
Phase 3:5
Drug Approvals
3
FDA:3
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 2
6 (50.0%)Phase 3
5 (41.7%)Phase 1
1 (8.3%)Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Helsinn Therapeutics (U.S.), Inc
- Target Recruit Count
- 300
- Registration Number
- NCT02296164
- Locations
- 🇺🇸
Investigator Site, Fairfax, Virginia, United States
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Phase 3
Completed
- Conditions
- CachexiaNon-Small Cell Lung Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- Helsinn Therapeutics (U.S.), Inc
- Target Recruit Count
- 513
- Registration Number
- NCT01395914
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Phase 3
Completed
- Conditions
- CachexiaNon-Small Cell Lung Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-07-04
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Helsinn Therapeutics (U.S.), Inc
- Target Recruit Count
- 484
- Registration Number
- NCT01387269
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Phase 3
Completed
- Conditions
- CachexiaNon-Small Cell Lung Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-07-04
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Helsinn Therapeutics (U.S.), Inc
- Target Recruit Count
- 495
- Registration Number
- NCT01387282
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
Phase 2
Completed
- Conditions
- Gastrointestinal Dysmotility
- Interventions
- Drug: Saline Solution for Injection
- First Posted Date
- 2011-01-20
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Helsinn Therapeutics (U.S.), Inc
- Target Recruit Count
- 320
- Registration Number
- NCT01280344
- Prev
- 1
- 2
- Next
News
No news found